Agilent helps researchers at Abbvie uncover potential target using CAR T therapeutics Agilent case study: AbbVie Though the weapons used in the battle against cancer come from a wide range of disciplines and approaches, one fundamental goal has remained a constant in oncology: namely, the need to develop tools that recognize and selectively kill cancer cells. One recent advance in cancer therapies involves the re-engineering of T cells – a class of white blood cells that serve as part of our body's natural defense system – to make them even more highly suited for this task. A host of new tools for altering T cell behavior have come online in recent years, and one that has shown particular promise is the production of CAR T cells, so named because they contain a surface receptor

Join for free to read